Michelle L Gordon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2368222/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence of HIVâ€1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa. Clinical Infectious Diseases, 2008, 46, 1589-1597.	5.8	226
2	Inner-Shell Excitation Spectroscopy of the Peptide Bond:  Comparison of the C 1s, N 1s, and O 1s Spectra of Glycine, Glycyl-Glycine, and Glycyl-Glycine. Journal of Physical Chemistry A, 2003, 107, 6144-6159.	2.5	162
3	Inner shell excitation of glycine, glycyl-glycine, alanine and phenylalanine. Journal of Electron Spectroscopy and Related Phenomena, 2004, 137-140, 795-799.	1.7	76
4	High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. Aids, 2012, 26, 1679-1684.	2.2	76
5	Variability at Human Immunodeficiency Virus Type 1 Subtype C Protease Cleavage Sites: an Indication of Viral Fitness?. Journal of Virology, 2003, 77, 9422-9430.	3.4	60
6	Molecular Characteristics of Human Immunodeficiency Virus Type 1 Subtype C Viruses from KwaZulu-Natal, South Africa: Implications for Vaccine and Antiretroviral Control Strategies. Journal of Virology, 2003, 77, 2587-2599.	3.4	60
7	Outcomes after virologic failure of first-line ART in South Africa. Aids, 2010, 24, 1007-1012.	2.2	59
8	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis. EClinicalMedicine, 2019, 9, 26-34.	7.1	51
9	Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe. PLoS ONE, 2015, 10, e0144057.	2.5	50
10	Mapping Sites of Positive Selection and Amino Acid Diversification in the HIV Genome. Genetics, 2004, 167, 1047-1058.	2.9	49
11	Early Warning Indicators for First-Line Virologic Failure Independent of Adherence Measures in a South African Urban Clinic. AIDS Patient Care and STDs, 2013, 27, 657-668.	2.5	47
12	HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. International Journal of Antimicrobial Agents, 2021, 57, 106343.	2.5	47
13	The pharmacokinetic properties of HIV-1 protease inhibitors: A computational perspective on herbal phytochemicals. Heliyon, 2019, 5, e02565.	3.2	38
14	A Systematic Review Analyzing the Prevalence and Circulation of Influenza Viruses in Swine Population Worldwide. Pathogens, 2020, 9, 355.	2.8	32
15	Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors. European Journal of Medicinal Chemistry, 2021, 217, 113330.	5.5	29
16	Tracing the origin of Brazilian HTLV-1 as determined by analysis of host and viral genes. Aids, 2006, 20, 780-782.	2.2	24
17	An overview of influenza A virus genes, protein functions, and replication cycle highlighting important updates. Virus Genes, 2022, 58, 255-269.	1.6	22
18	Resistance to antiretroviral drugs in newly diagnosed, young treatmentâ€naÃ⁻ve HIVâ€positive pregnant women in the province of KwaZuluâ€Natal, South Africa. Journal of Medical Virology, 2011, 83, 1508-1513.	5.0	21

MICHELLE L GORDON

#	Article	IF	CITATIONS
19	MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clinical Pharmacology and Therapeutics, 2003, 74, 195-196.	4.7	19
20	Drug Resistance and Coreceptor Usage in HIV Type 1 Subtype C-Infected Children Initiating or Failing Highly Active Antiretroviral Therapy in South Africa. AIDS Research and Human Retroviruses, 2012, 28, 324-332.	1.1	19
21	BioAfrica's HIV-1 proteomics resource: combining protein data with bioinformatics tools. Retrovirology, 2005, 2, 18.	2.0	18
22	Genetic Characteristics, Coreceptor Usage Potential and Evolution of Nigerian HIV-1 Subtype G and CRF02_AG Isolates. PLoS ONE, 2011, 6, e17865.	2.5	17
23	Drug Resistance Pattern of HIV Type 1 Isolates Sampled in 2007 from Therapy-Naive Pregnant Women in North-Central Nigeria. AIDS Research and Human Retroviruses, 2012, 28, 115-118.	1.1	17
24	Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. International Journal of Antimicrobial Agents, 2016, 48, 158-162.	2.5	16
25	HIV-1 subtype C envelope characteristics associated with divergent rates of chronic disease progression. Retrovirology, 2010, 7, 92.	2.0	15
26	Treatment options after virological failure of first-line tenofovir-based regimens in South Africa. Aids, 2016, 30, 1137-1140.	2.2	15
27	Molecular dynamic mechanism(s) of inhibition of bioactive antiviral phytochemical compounds targeting cytochrome P450 3A4 and P-glycoprotein. Journal of Biomolecular Structure and Dynamics, 2020, , 1-11.	3.5	13
28	Deciphering transmission dynamics and spillover of avian influenza viruses from avian species to swine populations globally. Virus Genes, 2021, 57, 541-555.	1.6	13
29	A systematic review of influenza A virus prevalence and transmission dynamics in backyard swine populations globally. Porcine Health Management, 2022, 8, 10.	2.6	13
30	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 2012, 433, 410-420.	2.4	12
31	Tuberculous meningitis is associated with higher cerebrospinal HIV-1 viral loads compared to other HIV-1-associated meningitides. PLoS ONE, 2018, 13, e0192060.	2.5	11
32	HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 384-389.	2.1	8
33	Minority HIV-1 drug-resistant mutations and prevention of mother-to-child transmission: perspectives for resource-limited countries. AIDS Reviews, 2014, 16, 187-98.	1.0	8
34	Review of genome sequencing technologies in molecular characterization of influenza A viruses in swine. Journal of Veterinary Diagnostic Investigation, 2022, 34, 177-189.	1.1	7
35	Analysis of Dominant HIV Quasispecies Suggests Independent Viral Evolution Within Spinal Granulomas Coinfected with Mycobacterium tuberculosis and HIV-1 Subtype C. AIDS Research and Human Retroviruses, 2016, 32, 262-270.	1.1	6
36	Gag-protease coevolution shapes the outcome of lopinavir-inclusive treatment regimens in chronically infected HIV-1 subtype C patients. Bioinformatics, 2019, 35, 3219-3223.	4.1	6

MICHELLE L GORDON

#	Article	IF	CITATIONS
37	Modulatory influences of antiviral bioactive compounds on cell viability, mRNA and protein expression of cytochrome P450 3A4 and P-glycoprotein in HepG2 and HEK293 cells. Bioorganic Chemistry, 2021, 107, 104573.	4.1	5
38	Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals. Viruses, 2017, 9, 330.	3.3	4
39	Candidate gene polymorphisms related to lipid metabolism in Asian Indians living in Durban, South Africa. Indian Journal of Medical Research, 2018, 148, 169.	1.0	4
40	Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch. Biomolecules, 2021, 11, 489.	4.0	3
41	Recombinant expression of HIV-1 protease using soluble fusion tags in Escherichia coli: A vital tool for functional characterization of HIV-1 protease. Virus Research, 2021, 295, 198289.	2.2	3
42	Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease. Journal of Biomolecular Structure and Dynamics, 2021, , 1-10.	3.5	2
43	Development of Dual-class Antiretroviral Drug Resistance in a Child Coinfected with HIV and Tuberculosis: A Case Report from KwaZulu-Natal, South Africa. Journal of Tropical Pediatrics, 2007, 55, 60-62.	1.5	1
44	A postâ€partum singleâ€dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving preâ€partum ZDV and intrapartum singleâ€dose nevirapine to prevent motherâ€to†child HIVâ€1 transmission. Journal of Medical Virology, 2015, 87, 1662-1667.	5.0	1
45	Vulnerable targets in HIV-1 Pol for attenuation-based vaccine design. Virology, 2021, 554, 1-8.	2.4	1
46	Structural effects of HIV-1 subtype C integrase mutations on the activity of integrase strand transfer inhibitors in South African patients. Journal of Biomolecular Structure and Dynamics, 2021, , 1-11.	3.5	1